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Abstract
Background: Studies suggest that Goal Directed Therapy (GDT) results in improved outcome
following major surgery. However, there is concern that pre-emptive use of inotropic therapy may
lead to an increased incidence of myocardial ischaemia and infarction.
Methods: Post hoc analysis of data collected prospectively during a randomised controlled trial of
the effects of post-operative GDT in high-risk general surgical patients. Serum troponin T
concentrations were measured at baseline and on day 1 and day 2 following surgery. Continuous
ECG monitoring was performed during the eight hour intervention period. Patients were followed
up for predefined cardiac complications. A univariate analysis was performed to identify any
associations between potential risk factors for myocardial injury and elevated troponin T
concentrations.
Results: GDT was associated with fewer complications, and a reduced duration of hospital stay.
Troponin T concentrations above 0.01 µg l-1 were identified in eight patients in the GDT group and
six in the control group. Values increased above 0.05 µg l-1 in four patients in the GDT group and
two patients in the control group. There were no overall differences in the incidence of elevated
troponin T concentrations. The incidence of cardiovascular complications was also similar. None
of the patients, in whom troponin T concentrations were elevated, developed ECG changes
indicating myocardial ischaemia during the intervention period. The only factor to be associated
with elevated troponin T concentrations following surgery was end-stage renal failure.
Conclusion: The use of post-operative GDT does not result in an increased incidence of
myocardial injury.
Background
The term Goal Directed Therapy (GDT) describes the use
of intra-venous fluid and inotropic agents to increase car-
diac output and related haemodynamic parameters to pre-
determined levels. Several studies suggest that the use of
GDT results in improved outcome, when commenced
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has been some concern that the pre-emptive use of ino-
tropic therapy in the absence of traditional indications for
such treatment, may lead to an increased incidence of
myocardial ischaemia and infarction. The incidence of
ischaemic heart disease in patients undergoing major sur-
gery is high [7], and it is possible that the use of pharma-
cological agents which increase myocardial work at a time
of increased physiological stress may result in an imbal-
ance of myocardial oxygen supply and demand. Patients
who do not readily achieve the pre-determined haemody-
namic goals may be at particular risk of such complica-
tions [8]. The absence of data describing the myocardial
effects of GDT is an important obstacle to the wider use of
this potentially beneficial treatment.
The use of cardiac troponin assays may provide a reliable
marker of post-operative myocardial injury. The high sen-
sitivity and specificity of these biochemical tests has
allowed the identification of a group of patients who have
sustained myocardial injury without detectable electrocar-
diograph (ECG) changes [9]. The use of such assays has
greatly influenced the approach to the management of
acute myocardial ischaemia [10]. Elevated serum tro-
ponin concentrations in the absence of ECG changes are
commonly identified following major general surgery,[9]
and are associated with poor outcome [11]. There is also
a high incidence of elevated troponin concentrations in
the critically ill [12,13], although it is unclear whether this
is due to myocardial ischaemia or sepsis-related myocar-
dial injury.
There is a need for more detailed information regarding
the myocardial effects of GDT and the troponin assay
would appear to be an ideal tool with which to evaluate
these in more detail. The aim of this study was to investi-
gate the effects of post-operative GDT on the incidence of
myocardial injury, identified through the measurement of
serum troponin T as well as conventional clinical means.
Methods
This was a post hoc analysis of data collected prospec-
tively during a randomised trial of the effects of GDT in
patients undergoing major surgery. This study was
approved by the Local Research Ethics Committee of St
George's Healthcare National Health Service Trust. A
detailed description of patient recruitment, clinical man-
agement and outcome data is provided in the original
manuscript [4]. Exclusion criteria included acute myocar-
dial ischaemia. Patients were monitored continuously
during the eight hour intervention period. The GDT pro-
tocol required reductions in the dose of dopexamine in
the event of tachycardia or myocardial ischaemia. Blood
samples were taken at baseline and on the morning of the
first and second post-operative days. Serum troponin T
was measured by an automated technique in the chemical
pathology laboratory at St George's Hospital (Elecsys
2010, Roche Diagnostics Ltd., Lewes, UK). Troponin T
concentrations below 0.01 µg l-1 were given a value of zero
for the purposes of analysis. Patients were followed up for
60 days to identify complications which were defined pro-
spectively.
Data are presented as mean (SD) where normally distrib-
uted and median (IQR) where not normally distributed.
Normality was tested with the Kolmogorov-Smirnov test.
Continuous data were analysed with the t test where nor-
mally distributed and the Mann Whitney U test where not
normally distributed. Differences in physiological trends
were assessed using repeated measures analysis of vari-
ance (ANOVA) with Bonferroni's correction. Univariate
analysis was performed to test associations between
potential risk factors for myocardial injury and elevated
troponin T concentrations. Analysis was performed using
GraphPad Prism version 4.0 for Windows (GraphPad
Software, San Diego, USA) and significance was set at p <
0.05.
Results
122 patients were recruited between November 2002 and
August 2004. 62 patients were randomised to GDT and 60
patients to control treatment. Baseline data and manage-
ment protocols are presented in detail in the original
manuscript [4]. There were no significant differences
between the groups with respect to baseline demographic
data, type of surgery or inclusion criteria. Data describing
the incidence of co-existing disease and pre-operative car-
diac medication are presented in table 1. Surgical and
anaesthetic management were also similar in the two
groups. Fewer patients developed complications in the
GDT group (27 patients [44%] vs. 41 patients [68%] RR
0.64 [0.46–0.89]; p = 0.007). The total number of compli-
cations was also lower in the GDT group. Median dura-
tion of hospital stay in the GDT group was significantly
reduced (14 days [11–27] vs. 11 days [7–15]; p = 0.001).
There was no difference in 28 day mortality (6 patients
[9.7%] vs. 7 patients [11.7%]; p = 0.78).
Serum troponin T concentrations greater than 0.01 µg l-1
were identified in six patients in the control group and
eight patients in the GDT group (figure 1). Troponin T
concentrations above 0.05 µg l-1 were identified in two
patients in the control group and four patients in the GDT
group. Troponin T was normal at baseline but subse-
quently increased to greater than 0.05 µg l-1 in one patient
in the control group and three patients in the GDT group.
There were no overall differences in troponin T concentra-
tions between the groups. The incidence of cardiovascular
complications was also similar (table 2). Of the six con-
trol group patients, in whom there were elevated troponinPage 2 of 6
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ischaemic heart disease and two were diagnosed with
post-operative myocardial infarction. Of the eight GDT
group patients, in whom there were elevated troponin
concentrations, four had a pre-operative diagnosis of
ischaemic heart disease. One patient developed septic
shock, one suffered a brainstem stroke, one developed
atrial fibrillation, one developed left ventricular failure
and one developed cardiogenic shock with pulmonary
oedema. None of the patients in whom troponin T con-
centrations were elevated, developed ECG changes indi-
cating myocardial ischaemia during the eight hour
intervention period. Univariate analysis was performed to
establish which potential cardiac risk factors were associ-
ated with post-operative myocardial injury (defined by a
troponin T concentration of 0.01 or above). The only
characteristic associated with an elevated troponin con-
centration was end-stage renal failure (table 3). When
those patients with elevated troponin T at baseline were
excluded, there were no associations with any of the
potential risk factors tested.
During the intervention period, the oxygen delivery index
(DO2I) target of 600 ml min-1 m-2 was achieved by 49
patients in the GDT group (79%). This value was also
attained spontaneously by 27 patients in the control
group (45%) (p = 0.0002). The difference in DO2I
between the groups resulted from a comparable difference
in cardiac index, which resulted from greater heart rate (p
= 0.0001) and stroke volume (p = 0.0001) in the GDT
group, whilst mean arterial pressure remained similar in
the two groups throughout the intervention period (figure
2). Post-operative haemodynamic interventions are sum-
marised in table 4. One patient in the control group
received dopexamine at a dose of 1 µg kg-1 min-1 on the
instruction of clinical staff. Despite receiving maximal
therapy allowed by the protocol, 13 patients in the GDT
group did not achieve the goal for DO2I. In seven of these
patients the dose of dopexamine was reduced, in six
patients this was because of tachycardia and in one
Table 3: Univariate analysis of potential risk factors for post-operative myocardial injury and elevated troponin T concentration.
Potential risk factor for 
post-operative 
myocardial injury
Troponin T >0.01 at any time Troponin T >0.01 when normal at baseline
n p n p
Goal directed therapy 10 (16%) >0.99 6 (10%) >0.99
Ischaemic heart disease 7 (18%) 0.80 3 (8%) >0.99
End-stage renal failure 6 (46%) 0.008* 1 (8%) >0.99
Hypertension 13 (19%) 0.30 7 (10%) 0.75
Diabetes 3 (23%) 0.45 1 (8%) >0.99
COPD 2 (13%) >0.99 2 (13%) 0.64
Obesity 1 (20%) >0.99 0 (0%) -
Stroke 0 (0%) - 0 (0%) -
Vascular surgery 5 (18%) 0.78 3 (11%) 0.71
Pre-operative cardiac 
medication
12 (17%) 0.80 6 (9%) >0.99
* signifies statistical significance; COPD, chronic obstructive pulmonary disease
Table 1: Incidence of common co-existing diseases and pre-
operative cardiac medication in the goal directed therapy and 
control groups.
Disease Control GDT
Hypertension 35 (58%) 34 (55%)
Ischaemic heart disease 23 (38%) 18 (29%)
Chronic obstructive pulmonary disease 8 (13%) 8 (13%)
Diabetes 8 (13%) 6 (10%)
End-stage Renal Failure 6 (10%) 7 (11%)
Obesity 2 (3%) 3 (5%)
Stroke 7 (12%) 2 (3%)
Drug
β-blockade 15 (25%) 14 (23%)
ACE inhibitor 18 (30%) 18 (29%)
Calcium channel antagonist 14 (23%) 16 (26%)
Diuretics 19 (32%) 14 (23%)
Digoxin 5 (8%) 0 (0%)
Data presented as absolute value (%)
Table 2: Post-operative cardiovascular complications in Goal 
Directed Therapy (GDT) and control groups.
Complication Control group GDT group
Arrythmia 9 5
Acute heart failure 4 4
Myocardial infarction 3 0
Stroke 1 2
Severe sepsis/septic shock 9 1
Data presented as absolute values.Page 3 of 6
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patients in each group received epinephrine in order to
maintain cardiac index above 2.5 l min-1 m-2 as dictated
in the study protocol.
Discussion
This analysis suggests that the use of post-operative GDT
does not result in an increased incidence of myocardial
injury. The incidence of cardiovascular complications
identified by traditional clinical criteria was also similar in
the two groups. However, the heart rate in the GDT group
was significantly higher than that of the control group.
The study protocol required a reduction in the dose of
dopexamine in the event of tachycardia or myocardial
ischaemia. This aspect of study design may explain the
absence of cardiac sequelae in patients in the GDT group.
Patients in the GDT group received an average of 700 ml
more intra-venous fluid and the majority also received
low dose dopexamine. It is possible that the use of alter-
native treatment goals or interventions may have been
associated with different findings. The only risk factor
identified by univariate analysis as being associated with
elevated serum troponin T concentration was end-stage
renal failure. Multivariate analysis was therefore not per-
Table 4: Haemodynamic management of patients in Goal Directed Therapy (GDT) and control groups during the intervention period.
Control group GDT group p
Intra-venous fluid
Crystalloid (ml) 960 (335) 930 (221) 0.39
Colloid (ml) 1204 (898) 1907 (878) <0.0001
Blood (ml) 0 (0 – 485) 125 (0 – 734) 0.09
Vasoactive drugs
No. of patients receiving dopexamine 1 (2%) 55 (89%) <0.0001
Dose of dopexamine (µg kg-1 min-1) 0 (0 – 0) 0.75 (0.5 – 1.0) <0.0001
No. of patients receiving epinephrine 3 (5%) 2 (3%) 0.68
Data presented as mean (SD), median (IQR) or absolute value (%).
Post-operative troponin T measurements in patients randomised to the Control and Goal Directed Therapy (GDT) groupsFigure 1
Post-operative troponin T measurements in patients randomised to the Control and Goal Directed Therapy (GDT) groups.Page 4 of 6
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are a recognised feature of end-stage renal failure [14], this
finding still has significant prognostic value [15].
Despite long standing concerns that GDT may result in
myocardial ischaemia, few studies have evaluated this
hypothesis in detail. One study of 89 surgical patients, did
not identify an increased incidence of myocardial infarc-
tion associated with the use of catecholamines to achieve
haemodynamic goals [16]. A small study in vascular sur-
gical patients suggested the use of dopexamine to increase
oxygen delivery may not result in increased myocardial
oxygen demand [17]. Whilst a study of the use of GDT in
a mixed group of critically ill patients suggested that con-
tinued attempts to achieve haemodynamic goals in unre-
sponsive patients may increase the incidence of
myocardial ischaemia [8].
Although the current data suggests that GDT does not
result in an increased incidence of myocardial injury,
there are a number of weaknesses in the analysis pre-
sented. This was a post hoc analysis of data collected pro-
spectively during a small, single centre trial. The study was
not specifically designed to test the association between
potential cardiac risk factors and post-operative myocar-
dial injury. The low incidence of post-operative myocar-
dial injury identified in this study may explain the fact
that only one potential risk factor for myocardial injury
was associated with an elevation in troponin T concentra-
tion. Acute myocardial ischaemia was a specific exclusion
criterion, but no attempts were made to standardise car-
diac medications prior to surgery or stratify patients for
the presence of myocardial disease. There were no overall
differences in pre-operative cardiac medication or co-mor-
bidity. However, five patients in the control group were
taking digoxin prior to surgery compared to none in the
GDT group. The indications for these prescriptions are not
known. The use of cardiac troponins appears to be a very
reliable method of identifying post-operative myocardial
injury [9,11]. However, increased plasma concentrations
of troponins may relate not to acute myocardial ischaemia
but to other mechanisms of injury such as sepsis [13]. It
appears that this may also have been the case in the
present study. Post-operative elevations in troponin con-
centrations in the absence of ECG changes have been
identified previously in general surgical patients [9], and
have prognostic significance [11]. Troponin assays would
therefore appear to be the most effective method of iden-
tifying myocardial injury resulting from the use of GDT.
Conclusion
The use of post-operative GDT does not appear to result in
an increased incidence of myocardial injury detected
through clinical, electrocardiographic or biochemical
means. GDT was not associated with an increased inci-
dence of clinically significant cardiovascular complica-
tions.
Key messages
• Goal directed therapy (GDT) appears to improve out-
come following major surgery
• There is concern that the pre-emptive use of inotropic
therapy may result in an increased incidence of myocar-
dial ischaemia
• This analysis suggests GDT does not affect the incidence
of myocardial injury detected either through biochemical
or clinical methods
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